Avanir Relying On PBA Drug Nuedexta For Success
This article was originally published in The Pink Sheet Daily
Executive Summary
Approved last year for pseudobulbar affect and gradually gaining sales and formulary adoption, Nuedexta will be studied in additional CNS indications.
You may also be interested in...
Hill Democrats Continue Inquiries Into High Prices For New Versions Of Old Drugs; Avanir's Nuedexta And URL Pharma's Colcrys Targeted
Letters from Sen. Kohl and Reps. Waxman, Pallone and DeGette are reminiscent of the recent uproar over pricing for KV's Makena.
Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift
Pfizer retains its lead in race to bring a novel oral RA drug to market
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.